March 31, 2021
2 min watch
Save
VIDEO: Oral selective estrogen receptor degraders 'incredibly' exciting in breast cancer
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Patrick Borgen, MD, chair of the department of surgery at Maimonides Medical Center, discussed the potential of using oral selective estrogen receptor degraders, or SERDs, in breast cancer at the 38th Annual Miami Breast Cancer Conference.
“This year we're going to be looking at oral versions of the injectable SERDs,” Borgen said. “We've been watching the field for a few years, but being able to avoid painful injections and use oral receptor degraders is something that we're incredibly excited about,” Borgen said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Borgen reports no financial disclosures.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.